Raising Capital for Life Sciences and Biotech in Australia: What Investors Actually Look For (And Where Most Founders Lose Them)

Australia is home to more than 1,600 biotech and medtech companies. Over 80% of them are small to medium enterprises. Most are pre-revenue. Most are burning cash on R&D with no clear timeline to commercialisation. And most of them are raising capital in ways that make it harder than it needs to be.

I've spent 17 years inside the private capital ecosystem. I've watched thousands of life science founders pitch to investors. The pattern of what works and what doesn't is clear, and it has very little to do with the quality of the science.

The founders who close rounds in biotech and life sciences in Australia aren't necessarily running the best labs. They're the ones who understand how investors think, what signals build confidence, and why communication is the infrastructure that holds a raise together.

Here's what the data says about raising capital for life sciences and biotech in Australia in 2026, and where the gap between great science and funded science actually sits.

The Investor Appetite Is Real. The Execution Gap Is Bigger.

From our 2026 Wholesale Investor Survey of more than 100 active private market participants, 31% of investors plan to actively deploy into HealthTech and MedTech in 2026. Another 30% are targeting Life Sciences and BioTech specifically.

That puts life sciences in the top five sectors for active capital deployment in Australia this year, alongside Deep Tech (37%), Technology broadly (38%), and Private Equity (34%).

The appetite is there. But appetite doesn't mean access.

When you look at where the friction actually sits, the problem isn't capital supply. It's the way life science founders engage with that capital. The communication gap between scientific founders and private market investors in Australia is wider in biotech than in any other sector I've seen.

Who Is Actually Writing Cheques in Australian Life Sciences?

This is the first thing most biotech founders get wrong. They assume the money is coming from specialist life science VCs and institutional biotech funds.

Some of it is. Brandon Capital closed its sixth fund at A$439 million in 2025, making it Australia's largest life sciences investor. WEHI Ventures has a $66 million fund backing pre-seed biomedical ventures. There are dedicated biotech VC firms actively deploying.

But the majority of active capital in Australian private markets doesn't come from institutional funds. Our survey data shows that 44% of active investors are sophisticated or wholesale individuals making their own allocation decisions. Another 25% are founder-investors.

That's nearly 70% of the active investor base making personal, conviction-driven decisions. They are not sitting in an investment committee reviewing term sheets through a formal process.

They're reading your materials alone, on a laptop, often late at night, trying to figure out if they trust you enough to write a cheque.

This changes everything about how you should raise.

If your pitch deck reads like it was written for a biotech-specialist VC, you've already lost most of your addressable investor market. The sophisticated individual investor who has deep operational experience in financial services (49% of our survey respondents) or sales and go-to-market (31%) needs a very different communication approach than a partner at a life sciences fund.

They need commercial clarity, not scientific complexity.

What Life Science Investors Care About Before the First Meeting

Our survey asked investors which factors most influence their decision to engage with a direct company opportunity before taking a meeting. In life sciences, three factors dominate.

Management track record: 77%. This is the number one trust signal across all sectors, but it matters most in biotech. Investors know that the science is uncertain. What they're really betting on is whether the team can navigate that uncertainty. Previous exits, industry tenure, clinical development experience, and regulatory pathway knowledge. If your founding team has it, lead with it. If it doesn't, surround yourself with advisors and board members who do.

24% of our survey respondents have direct operational expertise in Healthcare, Pharma, or BioTech. These investors will evaluate your team's scientific credibility. But the other 76% are evaluating something else entirely: can this team execute?

Commercial traction: 56%. For pre-revenue biotech, this translates differently than in SaaS or consumer companies. Traction in life sciences means pilot partnerships, licensing discussions, preclinical data milestones, clinical trial initiation, or regulatory pathway clarity. It means evidence that the science is moving toward a commercial outcome, not just that the science is interesting.

The founders who fail here are those who present 40 slides on molecular biology and zero on commercial strategy.

Path to liquidity: 47%. This is where the Australian market diverges sharply from the US. In our survey, lack of liquidity and exit options was cited as the number one frustration by 52% of investors. More than half.

In Australian biotech, the exit landscape is constrained. ASX biotech listings have a mixed track record. Trade sales to global pharma require scale that most Australian biotechs haven't reached.

And the typical venture horizon of 5 to 7 years feels uncomfortably long for investors who told us their preferred liquidity horizon is 3 to 5 years (47% of respondents).

If you can't articulate a specific, credible path to liquidity in your biotech raise, you're ignoring the biggest concern of your investor base.

RELATED: Raising Capital in Australia in 2026: What Active Investors Actually Want (And What Most Founders Get Wrong)

Why Cancer Drugs Attract Early Capital (And What It Teaches Every Biotech Founder)

Oncology remains the most well-funded therapeutic area in biotech globally. Billions flow into early-stage cancer companies every year, many of them pre-revenue, pre-clinical, years from any commercial outcome. The scientific risk is enormous. The failure rates are brutal. Historically, only around 3.4% of oncology therapeutics make it through clinical trials to market.

So why does the money keep coming?

Because the investment decision isn't purely scientific. It's personal.

One in two Australians will be diagnosed with cancer by the age of 85. Close to one million Australians have been diagnosed in the last decade alone. Nearly 170,000 new cases are expected this year. Every investor in your cap table has been touched by cancer. A parent. A partner. A friend. Themselves.

When a high-net-worth investor or family office principal sits across from a founder developing a potential cancer therapeutic, they're not just evaluating a risk-return profile. They're remembering sitting in a waiting room. They're remembering a phone call that changed everything. The science becomes personal in a way that a SaaS dashboard or a fintech product never will.

This is the dynamic that most biotech founders completely miss. And it applies well beyond oncology.

Our 2026 Investor Survey asked investors about problems or causes they have personal experience with or deep conviction about. The results reveal the emotional architecture behind life science investing:

• 25% cited aging, longevity, or elder care. These are investors who have watched parents decline. They understand the problem in their bones.

• 16% cited mental health and well-being. A growing area of personal conviction, particularly post-pandemic.

• 13% cited chronic illness or rare disease. These investors often have the deepest, most personal connection to the science. A child with a rare condition. A sibling with a chronic diagnosis.

• 34% cited food security and agriculture. For agri-biotech companies, this conviction runs through regional and family-office investors who have lived the problem.

  
  

Here's what this means for how you raise: when you're pitching to institutional VCs and specialist biotech funds, lead with the science. They have the training to evaluate your mechanism of action, your preclinical data, and your regulatory pathway. That's their language.

But when you're pitching to high net worth and family office investors, and remember, they represent the majority of active capital in Australian private markets, lead with the patient. Lead with the human problem. Lead with the story of why this disease matters and who it affects.

The best biotech founders I've watched raise capital don't open with a molecular diagram. They open with a person. "Every year, 15,000 Australians are diagnosed with this condition. There is no effective treatment. Here's what that looks like for a family." Then they bridge to the science. Then they show the commercial pathway.

That sequence matters. The humanisation of the science is what creates the emotional bridge between a sophisticated investor's personal experience and their willingness to write a cheque into a high-risk, pre-revenue biotech company.

This is not manipulation. It's alignment. You're connecting the investor's lived experience with the problem your science is trying to solve. That connection is what turns a "maybe" into a cheque, and it's what turns a first cheque into a follow-on investment when the clinical timeline extends, and the runway gets tight.

The institutional money follows the data. The private money follows the conviction. In Australian life sciences, private money is the majority of the market. Act accordingly.

The Structural Advantage Most Biotech Founders Underutilise

Australia has a genuine structural advantage in life sciences R&D that most founders either don't understand or fail to communicate effectively to investors.

The R&D Tax Incentive provides a refundable tax offset of up to 43.5% on eligible R&D expenditure for companies with less than $20 million in annual turnover. For biotech companies running clinical trials, this is significant. Clinical trial costs are explicitly eligible, and the exemption from the $4 million annual cap on refundable amounts for clinical trials makes Australia one of the most tax-efficient jurisdictions in the world for early-stage drug development.

The $20 billion Medical Research Future Fund (MRFF) provides grants across the health and medical research spectrum. The Biomedical Translation Fund was designed specifically to bridge the gap between lab and market. And the recently announced $13.6 million investment in a National One Stop Shop for clinical trials signals the government's ongoing commitment to making Australia a preferred destination for clinical research.

Here's the problem: most biotech founders treat these advantages as background noise in their pitch materials. They shouldn't be. For investors evaluating risk, the R&D Tax Incentive materially reduces cash burn. It extends the runway. It lowers the cost of failure. These are the kinds of signals that build investor confidence, and they should be front and centre in every biotech capital raise in Australia.

A life science company that can show investors: "Our effective R&D cost is 43.5% less than headline because of the R&D Tax Incentive, and here's what that means for our runway" has a materially different conversation than one that buries it in an appendix slide.

RELATED: 9 Reasons Investors Won't Back Your Business (And How to Fix Each One)

Deal Structures That Work in Australian Biotech

Our survey data on deal-structure preferences tell a clear story.

62% of investors prefer a priced equity round. This is the dominant preference across all sectors in Australia, and it applies to biotech too. Investors want to know what they own and what it's worth.

But here's where life sciences get interesting. 33% of investors expressed interest in private credit with equity or growth upside. And when we looked at credit return targets, 43% are seeking a hybrid yield with growth at 12% to 18% per annum.

For biotech companies with any form of revenue or licensing income, structuring a hybrid deal, one that provides income alongside equity participation, can open access to a completely different pool of capital. This is particularly relevant for medtech companies with existing product sales, diagnostic companies with revenue, or biotech companies with licensing royalties.

Most life science founders only think in terms of equity. The ones raising smartly in 2026 are structuring multiple instruments to access the full breadth of the Australian investor market.

SAFE notes, which are standard in US biotech raises, attracted only 23% interest from Australian investors. If you're raising on a SAFE because Y Combinator told you to, reconsider. Your Australian investor base wants price clarity.

The Communication Problem That Kills Biotech Raises

This is the part that nobody in the life sciences ecosystem honestly talks about.

The number one reason biotech raises stall in Australia is not the science. It's not the market. It's not the valuation. It's the founder's inability to communicate with investors in a way that builds and sustains confidence over time.

From our survey, 18% of investors said their biggest frustration is founders disappearing after they invest. In biotech, where timelines are long and milestones are uncertain, this is fatal. An investor who writes a cheque into a seed-stage biotech company and then hears nothing for six months doesn't just lose confidence in that deal. They lose confidence in the entire sector.

44% of investors said too much noise, not enough signal. In biotech, the noise is different. It's not spam pitch decks. It's dense, inaccessible scientific updates that investors can't parse. A 20-page clinical trial update written in medical jargon is noise. A one-page summary that says "We completed enrolment ahead of schedule, data readout is expected in Q3, and here's what that means for our timeline to approval" is a signal.

The founders who close biotech rounds consistently do three things differently:

• They translate science into a commercial narrative. Every update, every pitch, every communication frames the science in terms of its impact on the business outcome. Not what happened in the lab. What it means for the path to revenue, the path to approval, the path to exit.

• They communicate on a predictable cadence. Monthly investor updates. No exceptions. Even when there's nothing to report, the update says "Nothing material this month. Next milestone is X. We're on track." Silence is the enemy. Consistency builds trust.

• They address uncertainty directly. Biotech is uncertain. Investors know this. What they can't tolerate is a founder who pretends it isn't. The best biotech communicators say: "Here are the three things that could go wrong, here's the probability we assign to each, and here's our mitigation plan." That's confidence. Pretending everything is fine is not.

  
  

The Geographic Opportunity

73% of the investors in our survey focus on Australia as their primary geography. But 27% also target the United States, and 20% look at Singapore and Southeast Asia.

For Australian biotech companies, this geographic data matters. The US remains the primary market for biotech commercialisation and exit. Australian companies that can demonstrate a credible US regulatory and commercial strategy alongside their Australian R&D base have a significant advantage with investors.

The recently announced Australia-UK BioBridge under the Free Trade Agreement is creating new opportunities for cross-border clinical collaboration. And with FDA acceptance of Australian clinical trial data already established, the combination of Australian cost advantages and US commercial pathways is a compelling investment narrative.

But you have to tell that story. Most Australian biotech founders pitch as if they're building an Australian company. The ones who raise successfully pitch as if they're building a global company that happens to have its R&D advantage in Australia.

The Investor Expertise You're Not Leveraging

Our survey found that 63% of investors want to engage as advisors or mentors, making ad-hoc strategic calls. Only 42% want to be purely passive.

In biotech, this is a massive untapped resource. Your investor base includes people with deep operational experience in healthcare (24%), financial services (49%), and sales and go-to-market (31%). These are people who can help with commercial strategy, regulatory navigation, partnership introductions, and exit planning.

The problem is that most biotech founders don't ask. They take the cheque and go back to the lab. They miss the opportunity to turn their investor base into an operational asset.

The best life science founders I've observed build structured engagement programmes for their investors. Quarterly deep-dives on strategy. Specific asks around introductions. Advisory roles on commercial workstreams. This isn't just good practice. It directly drives follow-on investment and referral deal flow.

51% of investors said their follow-on capacity is situational. They'll reinvest if you give them a reason. In biotech, where follow-on rounds are essential to reach clinical milestones, losing this capital because you failed to communicate is an unforced error.

What the Best Biotech Founders Do Differently: A Summary

Lead with the team, not the molecule. 77% of investors say management track record is the top factor. Your team slide should be the strongest in the deck.

Humanise the science for private investors. The majority of your investor base is high-net-worth individuals and family offices, not specialist biotech VCs. Lead with the patient and the human problem before you lead with the mechanism of action. Personal conviction drives private capital in life sciences more than any financial model.

Make the R&D Tax Incentive a feature of your pitch, not a footnote. It materially changes the risk profile of Australian biotech investments. Quantify it.

Address liquidity directly. 52% of investors say it's their top frustration. Show a specific path: ASX listing timeline, trade sale targets, licensing milestones, or partnership structures that provide interim returns.

Price your round clearly. 62% prefer priced equity. Avoid SAFEs unless your investor base specifically requests them.

Structure for the full market. If you have any revenue or licensing income, consider a hybrid credit-equity structure to access the 33% of investors interested in private credit with upside.

Communicate monthly. In plain language. Translate clinical and scientific milestones into commercial implications. Every update should answer: what happened, what it means for the business, and what comes next.

Lower your minimum ticket to match reality. 43% of investors write first cheques between $25,000 and $100,000. Structure your round to let them in.

Build investor engagement into your operating rhythm. 63% want to help. Let them.

The Bigger Picture

Australian life sciences has world-class research infrastructure, competitive R&D cost advantages, and a growing pool of investors with a genuine appetite for the sector. The raw materials for a thriving biotech capital market are all here.

What's missing is the infrastructure that connects great science to engaged capital. The communication systems. The matching. The ongoing relationship management that turns a first cheque into follow-on investment, into referrals, into a syndicate that carries you through clinical milestones to an exit.

The biotech founders who will define the next decade of Australian life sciences won't just be the best scientists. They'll be the best communicators. The ones who treat investor relations as a core competency, not an afterthought.

The science has always been here. The capital is increasingly here. The gap is in the engagement layer between them.

Steve Torso is the founder of Wholesale Investor, Australia's largest sophisticated investor network with over 45,000 investors. The data cited are from the 2026 Wholesale Investor Survey of active private market participants. For broader insights on raising capital in Australia, read our complete 2026 investor data analysis.